drugset
drugset / Trial / NCT02364713

MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer

NCT02364713 ↗

Phase 2 Terminated 17 enrolled Mayo Clinic
RandomizedParallel-groupOpen-labelTreatment

Summary

This randomized phase II trial studies how well oncolytic measles virus encoding thyroidal sodium iodide symporter (MV-NIS) compared to investigator's choice chemotherapy works in treating patients with ovarian, fallopian, or peritoneal cancer. Measles virus, which has been changed in a certain way, may be able to kill tumor cells without damaging normal cells.

Timeline

Start
2015-03-13
Primary completion
2022-01-13
Completion
2022-01-13

Drugs

EvaluationDrugModalityDoseRoute
Comparator Doxorubicin Other / unclassified — Intravenous
Comparator Gemcitabine Small molecule — Intravenous
Subject MV-NIS Unknown — Other
Comparator Paclitaxel Small molecule — Intravenous
Comparator Topotecan Small molecule — Intravenous
Comparator Bevacizumab Monoclonal antibody — Intravenous

Indications

fallopian tube carcinosarcoma fallopian tube clear cell adenocarcinoma fallopian tube endometrioid adenocarcinoma fallopian tube mucinous adenocarcinoma fallopian tube serous adenocarcinoma fallopian tube transitional cell carcinoma ovarian carcinosarcoma ovarian clear cell adenocarcinoma ovarian endometrioid adenocarcinoma ovarian mucinous adenocarcinoma ovarian seromucinous carcinoma ovarian serous adenocarcinoma ovarian transitional cell carcinoma primary peritoneal serous adenocarcinoma undifferentiated ovarian carcinoma